Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02201342 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents
A Phase 1 study, sponsored by Mezzion Pharma Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT02201342 is a Phase 1 study that has completed, run by Mezzion Pharma Co.. The registered enrollment target is 36 participants.
The verdict
NCT02201342, a Phase 1 study, has completed, sponsored by Mezzion Pharma Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
To determine the pharmacokinetic profile and safety of udenafil in adolescents with Fontan physiology and to assess the short-term pharmacodynamic effect of udenafil on pharmacodynamic measures of exercise capacity, ventricular performance, and vascular function.
Interventions
- DRUG Udenafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02201342
The ClinicalTrials.gov registry entry for NCT02201342 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mezzion Pharma Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Udenafil is the first listed.
NCT02201342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02201342 about?
NCT02201342 is a clinical study titled "Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents". To determine the pharmacokinetic profile and safety of udenafil in adolescents with Fontan physiology and to assess the short-term pharmacodynamic effect of udenafil on pharmacodynamic measures of exercise capacity, ventricular performance, and vascular function.
What is the current status of trial NCT02201342?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2014-07. Estimated completion is 2015-04.
What interventions are being tested in trial NCT02201342?
The interventions under investigation include: Udenafil (DRUG).
Who is sponsoring clinical trial NCT02201342?
This trial is sponsored by Mezzion Pharma Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.